Viking treatments today
Vicing treatments
As of 04:00 pm
- 52 weeks
- 18.92 dollars
▼
81.86 dollars
- The target price
- 89.75 dollars
Viking Therapics Inc. Nasdak: VKTX Investors took a wild trip since the beginning of 2024. At one point, VKTX 375 % rose From the closing price on January 2, 2024, but it was a less fixed step. As of the closing market on April 15, 2025, the stock is in the range of 10 % of Jan 2024.
This week alone was brutal. Viking stocks about 12 % rose on the news that was preparing to start studying the third stage of the GLP-1 weight loss, VK2735. However, the arrow is struggling to obtain these gains as investors have a reminder of the practical costs of these drugs that could hinder adoption.
The GLP-1 drugs were among the best performance stocks in 2024. But the popularity of medicines came at a cost. And knowing how to manage this cost must be your decision to buy VKTX shares.
VK2735 has the possibilities for changing the game
If you are new to this place, the GLP-1 medications are under the skin in nature. This is an accurate medical way to say that patients need a shot that is managed under the skin. The same applies to VK2735, but also as the company may have a benefit to change the game.
Specifically, the company also tested an oral version of VK2735. This would remove one obstacle of patients with injections (i.e. fear of needles). In addition, some tests indicate that oral GLP-1 drugs may have a lower rate than side effects. However, the comparison could be that it takes longer to serve Weight loss results.
Investors sell the news coming from Washington
GLP-1 drugs provide tremendous benefits for patients. However, these benefits come at a huge cost. Until this lines are written, these medications are not covered by Medicare or Medicaid when used for weight loss.
GLP-1 shares such as Novo Nordisk A/S NYSE: NVO Elie Lily and Partners New York: Li On November 2024, the Biden Administration suggested a new base that would allow the GLP-1 to be covered by Medicare and Medicaid for low patients and older patients with BMI over 30 years. This coverage can be expanded by more than 7 million.
However, on April 11, Medicare and Medicaid Services (CMS) centers announced that it would not end the Biden base. The organization did not provide an additional comment. The Minister of Health and Humanitarian Services, Robert Kennedy, has expressed, while admitting that the GLP-1 drugs have a place in treating obesity, its preference to ensure that lifestyle changes are clear before transferring patients to obesity medications.
Regardless of the personal preferences of Amin Kennedy, the challenge will be the discovery of a regulatory framework for the GLP-1 drugs in terms of medical care and medical aid. Current estimates indicate that adding such coverage would significantly increase health care costs. In fact, Kennedy said that one of the estimates witnessed that the average employer would have to pay twice the current amount of health care costs for employees.
VKTX shares will require conviction
Viking Therapeutics today
89.75 dollars
Moderate purchase
Based on 13 analyst classifications
| The current price | 23.60 dollars |
|---|---|
| High expectations | 138.00 dollars |
| Average expectations | 89.75 dollars |
| Low expectations | 30.00 dollars |
Vicing treatments Details stock expectations
The ready -made meals for investors are that Viking Therapeutics has the ability to be a multi -sprayer in time. As of April 15, 2025, Therapeutics VIKING analyst expects Markbeat The purpose of the consensus price of $ 89.75, Which will be a profit of more than 288 %.
However, as investors have seen with other medical stocks, you will have to keep the arrow for several years before VK2735 gets approval. This is on the assumption that he gets approval. By this point, there is likely to be competition from other vital pharmaceutical products. In addition, the regulatory environment in Washington can reduce the potential upward trend of investors.
The arrow is popular with merchants, especially sellers on the open. Short attention in VKTX stockpiles more than 20 %This indicates that the arrow may not find a bottom yet.
After all, if you are still interested in reaching the plane, you will need to wait even after the company’s reports The profits on April 23. Trading is likely to be volatile from time to time, and even if the report is strong, you still have time to start a job.
Before you think of Vikings treatments, you will want to hear it.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts are quietly whispered to their customers to buy now before wiping the broader market … Viking Therapeutics was not in the list.
While Viking Therapeutics currently has a moderate purchase classification among analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Nuclear energy shares roar. It is the most important energy sector for this year. Cameco Corp, Paladin Energy and BWX Technologies increased by more than 40 % in 2024. The largest market movements can remain in front of us, and there are seven nuclear energy shares that may rise in the next few months. To cancel these indicators, enter your email address below.
